However, in many tumors, including triple-negative breast cancer, prostate cancer, nonsmall cell lung cancer, renal cell cancer, and melanoma, PD-1/PD-L1 blockade therapy can provide durable responses in only 20% of patients (Wu et al., 2019). This evidence concerns the gene CD274 and prostate carcinoma.